What is Leerink Partnrs’ Estimate for ELDN FY2029 Earnings?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Equities researchers at Leerink Partnrs issued their FY2029 earnings estimates for Eledon Pharmaceuticals in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.50) per share for the year. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.02).

A number of other brokerages also recently issued reports on ELDN. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Eledon Pharmaceuticals in a research report on Wednesday, November 20th. Guggenheim initiated coverage on Eledon Pharmaceuticals in a report on Tuesday, January 28th. They issued a “buy” rating and a $9.00 target price for the company.

Eledon Pharmaceuticals Trading Up 0.8 %

NASDAQ ELDN opened at $4.75 on Friday. Eledon Pharmaceuticals has a 52 week low of $1.52 and a 52 week high of $5.54. The business’s fifty day simple moving average is $4.40 and its 200-day simple moving average is $3.59.

Hedge Funds Weigh In On Eledon Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ELDN. Inspire Investing LLC purchased a new position in Eledon Pharmaceuticals during the fourth quarter worth about $802,000. Renaissance Technologies LLC increased its position in Eledon Pharmaceuticals by 57.1% during the 2nd quarter. Renaissance Technologies LLC now owns 136,773 shares of the company’s stock worth $361,000 after purchasing an additional 49,704 shares during the period. Geode Capital Management LLC raised its stake in shares of Eledon Pharmaceuticals by 9.7% during the 3rd quarter. Geode Capital Management LLC now owns 378,058 shares of the company’s stock worth $942,000 after buying an additional 33,569 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Eledon Pharmaceuticals in the 2nd quarter valued at approximately $80,000. Finally, Kera Capital Partners Inc. purchased a new stake in shares of Eledon Pharmaceuticals in the fourth quarter valued at approximately $106,000. Institutional investors and hedge funds own 56.77% of the company’s stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).